Mccabe Dominick
Short Bio of Prof. Dominick J H McCabe PhD, FRCPI, FESO, FAHA
Prof. Dominick McCabe is currently a Consultant Neurologist / Clinical Professor in Neurology, and Chairperson of the Vascular Neurology Research Foundation (VNRF.ie), Department of Neurology/Stroke Service, Tallaght University Hospital (TUH)-AMNCH/Trinity College Dublin (TCD), Ireland. He established and co-directs a 'daily, one-stop Rapid Access Stroke Prevention service', and established and chairs a weekly Neurovascular Multi-Disciplinary Team meeting. He has been instrumental in Clinical and Academic Neurology/Stroke Medicine development, training & education, serves on a number of advisory groups, and is a member of several international organisations, with fellowship of the ESO and AHA.
Prof McCabe is the PI / Co-PI / Collaborator in several national or international multi-centre research studies or trials, including the PI of the 'Optimal Antiplatelet Therapy in TIA and Ischaemic Stroke-International (OATS-I) study'. His Vascular Neurology Research group has conducted original studies which have shown that platelets may be excessively activated / hyper-reactive following TIA/ischaemic stroke, and that an important proportion of patients with ischaemic cerebrovascular disease are 'poorly-responsive' to antiplatelet agents with 'high on-treatment platelet reactivity (HTPR)' in the laboratory. They have also found an ongoing stimulus to increased platelet production and secretion, and enhanced platelet and endothelial activation and coagulation system potential after TIA/ischaemic stroke in patients with symptomatic compared with asymptomatic moderate-severe carotid stenosis, including in those who do not have micro-embolic signals (MES) on transcranial Doppler ultrasound. These data improve our understanding of the underlying biological mechanisms which may contribute to the disparity in the risk of TIA/stroke in subgroups of patients with recently symptomatic vs. asymptomatic carotid stenosis, and in subgroups of symptomatic patients with different plaque types and MES status.
He collaborated with colleagues to conduct recent systematic reviews on optimal antiplatelet therapy and the value of platelet biomarkers in patients with moderate-severe carotid stenosis, and a systematic review and meta-analysis on the potential value of platelet biomarkers at predicting the risk of recurrent vascular events after TIA or ischaemic stroke overall. He has also collaborated with international experts in Vascular Surgery, Interventional Neuroradiology and Vascular Neurology to assess restenosis rates following carotid endovascular treatment or endarterectomy, and to finalise the 2021 ESO Guidelines on the management of patients with carotid stenosis, and the 2017 & 2023 ESVS international guidelines on the management of patients with atherosclerotic carotid and vertebral artery stenosis.